Company Onconova Therapeutics Inc Nasdaq
Equities
US68232V1089
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oncology Therapeutics
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -.--% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -.--% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 15-01-18 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 13-08-31 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-23 |
Victor Moyo
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-23 |
Matthew Parris
CTO | Chief Tech/Sci/R&D Officer | - | 18-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 15-06-30 |
Jack Stover
BRD | Director/Board Member | 69 | 16-05-22 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 20-03-31 |
Steven Fruchtman
PSD | President | 73 | 15-01-18 |
Trafford Clarke
BRD | Director/Board Member | 66 | 22-12-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 25,301,009 | 21,604,002 ( 85.39 %) | 0 | 85.39 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+24.80% | 46.71B | |
+48.83% | 41.8B | |
-1.12% | 41.52B | |
-3.42% | 29.55B | |
+10.49% | 25.78B | |
-20.54% | 19.26B | |
+0.69% | 12.14B | |
-0.01% | 12.08B | |
+26.07% | 11.98B |